8-K: 10x Genomics Reports 5% Revenue Increase in Q1 2024, Driven by Spatial Products

10x Genomics announced a 5% year-over-year revenue increase for the first quarter of 2024, reaching $141 million, primarily fueled by growth in its Spatial product line.

Summary

• 10x Genomics reported a revenue of $141 million for the first quarter of 2024, which is a 5% increase compared to the $134.3 million reported in the same period of 2023.
• The revenue growth was primarily driven by the company's Spatial products.
• Gross margin decreased to 66% in Q1 2024 from 73% in Q1 2023, mainly due to a change in product mix with Xenium instruments.
• Operating expenses rose by 3% to $154.4 million, driven by higher legal, facilities, and IT costs, partially offset by lower personnel expenses.
• The company's operating loss was $61.5 million, compared to $52 million in the same quarter of the previous year.
• Net loss for the quarter was $59.9 million, compared to a net loss of $50.7 million in the first quarter of 2023.
• 10x Genomics is maintaining its full-year 2024 revenue guidance of $670 million to $690 million, which represents an 8% to 12% growth over 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While revenue increased, the decrease in gross margin and increase in net loss are concerning. The company is maintaining its guidance, which is a positive sign, but the overall financial performance is mixed.

Positives

• The company experienced a 5% increase in revenue year-over-year, reaching $141 million.
• Spatial product revenue showed strong growth.
• 10x Genomics launched four major new products in the quarter, setting a new standard for single cell and spatial biology.
• The company shipped Visium HD, which contributed to strong growth in Spatial revenue.
• There was significant customer trial of new GEM-X products.
• The company is maintaining its full-year revenue guidance, indicating confidence in future performance.

Negatives

• Gross margin decreased from 73% to 66% due to a change in product mix, particularly with Xenium instruments.
• Operating loss increased from $52 million to $61.5 million year-over-year.
• Net loss increased from $50.7 million to $59.9 million year-over-year.
• Lower quarter-end orders for Chromium were noted due to customer trials of new GEM-X products.

Risks

• The decrease in gross margin could impact profitability if not addressed.
• Increased operating expenses, particularly in legal, facilities, and IT, could continue to pressure earnings.
• The company's reliance on new product launches for growth carries the risk of slower adoption or market acceptance.
• The company's financial performance is subject to risks and uncertainties detailed in their SEC filings.

Future Outlook

10x Genomics is maintaining its full-year 2024 revenue guidance of $670 million to $690 million, representing 8% to 12% growth over full year 2023 revenue.

Management Comments

• Serge Saxonov, Co-founder and CEO of 10x Genomics, stated that the company delivered four major new products this quarter, setting a new standard for single cell and spatial biology.
• He also noted that Visium HD helped drive strong growth in Spatial and that a significant number of customers trialed new GEM-X products.

Industry Context

The announcement reflects the ongoing growth and competition in the single-cell and spatial biology markets, with 10x Genomics focusing on new product launches to maintain its position. The company's focus on spatial biology aligns with the increasing demand for high-resolution spatial analysis in research.

Comparison to Industry Standards

• Competitors like NanoString Technologies and Bio-Rad Laboratories also operate in the spatial and single-cell analysis markets.
• While 10x Genomics reported a 5% revenue increase, other companies in the sector have shown varying growth rates, reflecting the competitive landscape.
• The decrease in gross margin for 10x Genomics is a point of concern compared to industry benchmarks, where companies often strive for stable or increasing margins.
• The launch of new products like Visium HD and GEM-X powered Chromium products is consistent with the industry trend of innovation and technological advancement.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased gross margin.
• Employees may be affected by the company's cost management strategies.
• Customers will benefit from the new product launches and technological advancements.
• Suppliers may see changes in demand based on the company's product mix.

Next Steps

• 10x Genomics will host a conference call to discuss the first quarter 2024 financial results, business developments and outlook after market close on Tuesday, April 30, 2024.
• The company will continue to focus on the adoption and feedback of its new product launches to accelerate growth throughout the year.

Key Dates

Keywords

10x Genomics, single cell biology, spatial biology, genomics, Visium HD, GEM-X, Chromium, Xenium, financial results, revenue, gross margin, operating loss, net loss